Cambridge Heart Reports Results for the Three and Six Months Ended June 30, 2012

Cambridge Heart Reports Results for the Three and Six Months Ended June 30, 2012

a developer of non-invasive diagnostic tests for cardiac disease, today reported results for the three and six months ended June 30, 2012. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which will be filed with the Securities and Exchange Commission on August 14, 2012.

Using innovative technologies, Cambridge Heart addresses a key problem in cardiac diagnosis – the identification of those at risk of sudden cardiac death. Sudden cardiac arrest (SCA) accounts for approximately one third of all cardiac deaths, or approximately 300,000 deaths, in the United States each year – more than lung cancer, breast cancer and HIV/AIDS combined. Out-of-hospital survival is less than 8%, making prediction and prevention critically important. It is estimated that there are approximately 10 to 12 million heart attack and heart failure patients in the U.S. who can benefit from annual Microvolt T-Wave Alternans () testing. MTWA is a marker of SCA risk which is measured during a non-invasive treadmill test using Cambridge Heart’s proprietary technologies. The Company’s MTWA test is the only one of its kind that is reimbursed by Medicare under a National Coverage Policy.

Commenting on the results of the second quarter and recent events, Cambridge Heart CEO Ali Haghighi-Mood said, “As previously announced, in the second quarter revenue continued to be lower than expected, prompting the company to initiate a significant restructuring in order to reduce its cash burn. Under the new structure, we continue to support our customer base and distribution partners while exploring our strategic alternatives.” Mr. Haghighi-Mood added, “We are in the early stages of these exploratory activities, and look forward to providing an update in coming months.”

Total revenue for the second quarter ended June 30, 2012 was $461,000, compared to total revenue of $542,000 reported during the same period of 2011. The decrease in revenue compared to the same period in 2011 is largely attributable to less focus and resources spent on selling the stand-alone HearTwave II System as we transitioned to the MTWA Module strategy and the implementation of the no-charge MTWA Module program introduced last July.

Cost of sales for the second quarter of 2012 was $413,000, compared to $416,000 in the same period in 2011. Gross profit, as a percent of revenue, for the three months ended June 30, 2012 and 2011 was 10% and 23%, respectively. The decrease in gross profit compared to 2011 is mostly due to the cost of goods of the MTWA Modules shipped during the quarter in connection with the Company’s initiative with our OEM partner launched in July 2011 whereby the MTWA Module was provided to them at no charge.

Operating expenses for the second quarter of 2012 were $1,498,000, a decrease of $23,000, or 2%, compared to $1,521,000 in the second quarter of 2011. The decrease in operating expense is driven by lower selling, general and administrative costs.

The operating loss for the second quarter of 2012 was $1,449,000 compared to an operating loss of $1,396,000 for the same period last year. Included in the operating loss for the second quarter of 2012 was $150,000 of non-cash stock-based compensation expense, compared to $91,000 in the comparable 2011 period. The net loss for the quarter was $1,303,000, or $0.01 per share, compared to a net loss of $1,397,000, or $0.01 per share, in the comparable 2011 period.

Total revenue for the six months ended June 30, 2012 was $1,016,000, compared to total revenue of $1,179,000 reported during the same period of 2011.

Cost of sales for the first half of 2012 was $927,000, compared to $858,000 in the same period in 2011. Gross profit, as a percent of revenue, for the six months ended June 30, 2012 and 2011 was 9% and 27%, respectively.

Operating expenses for the six-month periods ended June 30, 2012 and 2011 were $3,205,000 and $3,046,000, respectively. The increase was due to broker and consultative fees incurred in connection with the issuance of the 2012 Notes.

The operating loss for the six months ended June 30, 2012 was $3,117,000 compared to an operating loss of $2,726,000 for the same period last year. Included in the operating loss for the six-month periods of 2012 and 2011 was $227,000 and $190,000, respectively, of non-cash stock-based compensation expense. The net loss for the 2012 period was $3,152,000, or $0.03 per share, compared to a net loss of $2,730,000, or $0.03 per share, in the comparable 2011 period.

The Company ended the second quarter with unrestricted cash and cash equivalents of $421,000. The cash used by operations was $2,759,000 for the six months ended June 30, 2012, compared to $2,536,000 for the same period in 2011. The Company believes that the existing resources and currently projected financial results are sufficient to fund operations into October of 2012.

As of June 30, 2012, the Company had a total of 124 million shares of common stock and common stock equivalents issued and outstanding, including the effect of converting the Series C-1 preferred stock and the Series D preferred stock into shares of common stock. In addition, there are options and warrants outstanding to purchase 58.0 million shares of common stock, bringing the fully diluted share count to 182 million shares of common stock.

Questions can be directed to the Company's management or its investor relations firm at the contact numbers provided.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company's products incorporate proprietary Microvolt T-Wave Alternans (MTWA) measurement technologies, including the patented Analytic Spectral Method and ultrasensitive disposable electrode sensors. The Company's MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.

Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB. For additional information, please refer to the Company's website at: .

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.